Literature DB >> 23416040

The α3β4* nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse.

Kia J Jackson1, Sarah S Sanjakdar, Pretal P Muldoon, J Michael McIntosh, M Imad Damaj.   

Abstract

The 15q25 gene cluster contains genes that code for the α5, α3, and β4 nicotinic acetylcholine receptor (nAChRs) subunits, and in human genetic studies, has shown the most robust association with smoking behavior and nicotine dependence to date. The limited available animal studies implicate a role for the α5 and β4 nAChR subunits in nicotine dependence and withdrawal; however studies focusing on the behavioral role of the α3β4* nAChR receptor subtype in nicotine dependence are lacking. Because of the apparent role of the α3β4* nAChR subtype in nicotine dependence, the goal of the current study was to better evaluate the involvement of this subtype in nicotine mediated behavioral responses. Using the selective α3β4* nAChR antagonist, α-conotoxin AuIB, we assessed the role of α3β4* nAChRs in acute nicotine, nicotine reward, and physical and affective nicotine withdrawal. Because α5 has also been implicated in nicotine dependence behaviors in mice and can form functional receptors with α3β4*, we also evaluated the role of the α3β4α5* nAChR subtype in nicotine reward and somatic nicotine withdrawal signs by blocking the α3β4* nAChR subtype in α5 nAChR knockout mice with AuIB. AuIB had no significant effect on acute nicotine behaviors, but dose-dependently attenuated nicotine reward and physical withdrawal signs, with no significant effect in affective withdrawal measures. Interestingly, AuIB also attenuated nicotine reward and somatic signs in α5 nAChR knockout mice. This study shows that α3β4* nAChRs mediate nicotine reward and physical nicotine withdrawal, but not acute nicotine behaviors or affective nicotine withdrawal signs in mice. The α5 subunit is not required in the receptor assembly to mediate these effects. Our findings suggest an important role for the α3β4* nAChR subtype in nicotine reward and physical aspects of the nicotine withdrawal syndrome.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23416040      PMCID: PMC3644352          DOI: 10.1016/j.neuropharm.2013.01.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  44 in total

1.  The distribution of mRNA encoded by a new member of the neuronal nicotinic acetylcholine receptor gene family (alpha 5) in the rat central nervous system.

Authors:  E Wada; D McKinnon; S Heinemann; J Patrick; L W Swanson
Journal:  Brain Res       Date:  1990-08-27       Impact factor: 3.252

2.  Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine.

Authors:  M R Picciotto; M Zoli; R Rimondini; C Léna; L M Marubio; E M Pich; K Fuxe; J P Changeux
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

3.  Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour.

Authors:  S L Handley; S Mithani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-08       Impact factor: 3.000

4.  Inhibition of nicotine-induced hippocampal norepinephrine release in rats by alpha-conotoxins MII and AuIB microinjected into the locus coeruleus.

Authors:  Y Fu; S G Matta; J M McIntosh; B M Sharp
Journal:  Neurosci Lett       Date:  1999-05-07       Impact factor: 3.046

5.  Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems.

Authors:  M Zoli; N Le Novère; J A Hill; J P Changeux
Journal:  J Neurosci       Date:  1995-03       Impact factor: 6.167

6.  Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit.

Authors:  Ramiro Salas; Fredalina Pieri; Mariella De Biasi
Journal:  J Neurosci       Date:  2004-11-10       Impact factor: 6.167

7.  Alpha3beta4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons.

Authors:  M W Quick; R M Ceballos; M Kasten; J M McIntosh; R A Lester
Journal:  Neuropharmacology       Date:  1999-06       Impact factor: 5.250

8.  The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.

Authors:  Ramiro Salas; Kimberly D Cook; Laura Bassetto; Mariella De Biasi
Journal:  Neuropharmacology       Date:  2004-09       Impact factor: 5.250

9.  Nicotinic agonists administered into the fourth ventricle stimulate norepinephrine secretion in the hypothalamic paraventricular nucleus: an in vivo microdialysis study.

Authors:  S G Matta; J G McCoy; C A Foster; B M Sharp
Journal:  Neuroendocrinology       Date:  1995-04       Impact factor: 4.914

10.  alpha-conotoxin AuIB selectively blocks alpha3 beta4 nicotinic acetylcholine receptors and nicotine-evoked norepinephrine release.

Authors:  S Luo; J M Kulak; G E Cartier; R B Jacobsen; D Yoshikami; B M Olivera; J M McIntosh
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

View more
  32 in total

1.  The role of alpha5 nicotinic acetylcholine receptors in mouse models of chronic inflammatory and neuropathic pain.

Authors:  Deniz Bagdas; Shakir D AlSharari; Kelen Freitas; Matthew Tracy; M Imad Damaj
Journal:  Biochem Pharmacol       Date:  2015-04-28       Impact factor: 5.858

2.  The α3β4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies.

Authors:  P P Muldoon; K J Jackson; E Perez; J L Harenza; S Molas; B Rais; H Anwar; N T Zaveri; R Maldonado; U Maskos; J M McIntosh; M Dierssen; M F Miles; X Chen; M De Biasi; M I Damaj
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

3.  Differences in mechanisms underlying reinstatement of cigarette smoke extract- and nicotine-seeking behavior in rats.

Authors:  Sarah J Cross; Daisy D Reynaga; Michelle Cano; James D Belluzzi; Nurulain T Zaveri; Frances M Leslie
Journal:  Neuropharmacology       Date:  2019-11-06       Impact factor: 5.250

Review 4.  Nicotine withdrawal.

Authors:  Ian McLaughlin; John A Dani; Mariella De Biasi
Journal:  Curr Top Behav Neurosci       Date:  2015

5.  Pharmacological stress is required for the anti-alcohol effect of the α3β4* nAChR partial agonist AT-1001.

Authors:  Andrea Cippitelli; Gloria Brunori; Kelly A Gaiolini; Nurulain T Zaveri; Lawrence Toll
Journal:  Neuropharmacology       Date:  2015-02-14       Impact factor: 5.250

6.  The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats.

Authors:  Menglu Yuan; Ariana M Malagon; Dennis Yasuda; James D Belluzzi; Frances M Leslie; Nurulain T Zaveri
Journal:  Behav Brain Res       Date:  2017-07-08       Impact factor: 3.332

7.  Discovery of peptide ligands through docking and virtual screening at nicotinic acetylcholine receptor homology models.

Authors:  Abba E Leffler; Alexander Kuryatov; Henry A Zebroski; Susan R Powell; Petr Filipenko; Adel K Hussein; Juliette Gorson; Anna Heizmann; Sergey Lyskov; Richard W Tsien; Sébastien F Poget; Annette Nicke; Jon Lindstrom; Bernardo Rudy; Richard Bonneau; Mandë Holford
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

Review 8.  Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction.

Authors:  Ruthie E Wittenberg; Shannon L Wolfman; Mariella De Biasi; John A Dani
Journal:  Neuropharmacology       Date:  2020-07-29       Impact factor: 5.250

Review 9.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

10.  Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats.

Authors:  Moe Igari; Jon C Alexander; Yue Ji; Xiaoli Qi; Roger L Papke; Adrie W Bruijnzeel
Journal:  Neuropsychopharmacology       Date:  2013-08-21       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.